"These compelling biomarker data provide further evidence that supports the ongoing development of fosgonimeton and our pipeline of HGF/MET-modulating compounds," said Mark Litton, Ph.D., Chief Executive Officer of Athira Pharma. "Our clinical and preclinical data continue to support the potential neuroprotective and disease-modifying properties of enhancing the HGF/MET neurotrophic system. We are excited by our progress with the ongoing Phase 2/3 LIFT-AD clinical study of fosgonimeton in this same patient population and look forward to completing enrollment of this potentially pivotal study in mid-2023 with topline data in early 2024."